Quinoline and Quinoxaline Derivatives as Kinase Inhibitors
申请人:Parton Andrew Harry
公开号:US20130296338A1
公开(公告)日:2013-11-07
A series of quinoline and quinoxaline derivatives comprising a fluorinated ethyl side-chain, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
Disclosed are a series of quinoline and quinoxaline derivatives comprising a fluorinated ethyl side-chain, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. The compounds are of general formula (I):
QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS
申请人:UCB Pharma, S.A.
公开号:EP2614061A1
公开(公告)日:2013-07-17
US9029392B2
申请人:——
公开号:US9029392B2
公开(公告)日:2015-05-12
[EN] QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLINE ET DE QUINOXALINE À TITRE D'INHIBITEURS DE KINASES
申请人:UCB PHARMA SA
公开号:WO2012032334A1
公开(公告)日:2012-03-15
A series of quinoline and quinoxaline derivatives comprising a fluorinated ethyl side-chain, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.